NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!!

Similar documents
e.com/watch?v=hz1f yhvojr4 e.com/watch?v=kmy xd6qeass

Statistical Considerations in Study Development: How to write good objectives!

Statistics for Clinical Trials: Basics of Phase III Trial Design

Fundamental Clinical Trial Design

This is a repository copy of Practical guide to sample size calculations: superiority trials.

Methodological aspects of non-inferiority and equivalence trials

Objectives. Quantifying the quality of hypothesis tests. Type I and II errors. Power of a test. Cautions about significance tests

Biostatistics 3. Developed by Pfizer. March 2018

Determining the size of a vaccine trial

Inferential Statistics

Power & Sample Size. Dr. Andrea Benedetti

Sheila Barron Statistics Outreach Center 2/8/2011

Common Statistical Issues in Biomedical Research

Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials

This is a repository copy of Practical guide to sample size calculations: non-inferiority and equivalence trials.

Research Questions, Variables, and Hypotheses: Part 2. Review. Hypotheses RCS /7/04. What are research questions? What are variables?

Sample Size Considerations. Todd Alonzo, PhD

Statistical Power Sampling Design and sample Size Determination

Business Statistics Probability

Chapter 12. The One- Sample

Methods for Determining Random Sample Size

Abdul Latif Jameel Poverty Action Lab Executive Training: Evaluating Social Programs Spring 2009

SAMPLING AND SAMPLE SIZE

SAMPLE SIZE IN CLINICAL RESEARCH, THE NUMBER WE NEED

Sample Size and Power

European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)

An introduction to power and sample size estimation

Guidance Document for Claims Based on Non-Inferiority Trials

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Sample Size and Power. Objectives. Take Away Message. Laura Lee Johnson, Ph.D. Statistician

Power of a Clinical Study

Non-inferiority trials and switch from non-inferiority to superiority. D Costagliola U 943 INSERM and UPMC Paris 06

Statistical Analysis Plan

Clinical Trials Lecture 4: Data analysis

15.301/310, Managerial Psychology Prof. Dan Ariely Recitation 8: T test and ANOVA

Planning Sample Size for Randomized Evaluations.

Welcome to our e-course on research methods for dietitians

To open a CMA file > Download and Save file Start CMA Open file from within CMA

Sample size for clinical trials

Lesson 11.1: The Alpha Value

Developing and Testing Hypotheses Kuba Glazek, Ph.D. Methodology Expert National Center for Academic and Dissertation Excellence Los Angeles

Biostatistical Aspects of Rational Clinical Trial Designs

Department of OUTCOMES RESEARCH

Chapter 23. Inference About Means. Copyright 2010 Pearson Education, Inc.

Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha

OCW Epidemiology and Biostatistics, 2010 David Tybor, MS, MPH and Kenneth Chui, PhD Tufts University School of Medicine October 27, 2010

EFFECTIVE MEDICAL WRITING Michelle Biros, MS, MD Editor-in -Chief Academic Emergency Medicine

How to craft the Approach section of an R grant application

Statistical probability was first discussed in the

Psy201 Module 3 Study and Assignment Guide. Using Excel to Calculate Descriptive and Inferential Statistics

Overview. Goals of Interpretation. Methodology. Reasons to Read and Evaluate

Applied Statistical Analysis EDUC 6050 Week 4

Experimental Research in HCI. Alma Leora Culén University of Oslo, Department of Informatics, Design

CHAPTER NINE DATA ANALYSIS / EVALUATING QUALITY (VALIDITY) OF BETWEEN GROUP EXPERIMENTS

Adaptive Treatment Arm Selection in Multivariate Bioequivalence Trials

Hypothesis Testing. Richard S. Balkin, Ph.D., LPC-S, NCC

BIOSTATISTICAL METHODS

Economics 345 Applied Econometrics

Biost 524: Design of Medical Studies

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

Sample size calculations: basic principles and common pitfalls

A Method for Utilizing Bivariate Efficacy Outcome Measures to Screen Agents for Activity in 2-Stage Phase II Clinical Trials

Psychology Research Process

Statistical Considerations in Pilot Studies

January 2017 STARTING THE NEW YEAR A NEW WAY. It takes courage to grow up and turn out to be who you really are. e.e. cummings

One-Way Independent ANOVA

Understanding noninferiority trials

1 The conceptual underpinnings of statistical power

Patrick Breheny. January 28

A Case Study: Two-sample categorical data

Top 10 Tips for Successful Searching ASMS 2003

Power Analysis: A Crucial Step in any Social Science Study

Cost-Utility Analysis (CUA) Explained

SMART Clinical Trial Designs for Dynamic Treatment Regimes

Practical Statistical Reasoning in Clinical Trials

Making comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups

Statistical Essentials in Interpreting Clinical Trials Stuart J. Pocock, PhD

Concepts of Clinical Trials

Economics 2010a. Fall Lecture 11. Edward L. Glaeser

Still important ideas

A Brief (very brief) Overview of Biostatistics. Jody Kreiman, PhD Bureau of Glottal Affairs

Frequently Asked Questions From Colleagues or Members, Tips and Pointers

WLF 315 Wildlife Ecology I Lab Fall 2012 Sampling Methods for the Study of Animal Behavioral Ecology

NCIC CTG New Investigators Course: Workshop II. Dongsheng Tu and Penelope Bradbury August 21-23, 2013

Letter to the teachers

Introduction to statistics Dr Alvin Vista, ACER Bangkok, 14-18, Sept. 2015

The Pretest! Pretest! Pretest! Assignment (Example 2)

Variables Research involves trying to determine the relationship between two or more variables.

MULTIPLE LINEAR REGRESSION 24.1 INTRODUCTION AND OBJECTIVES OBJECTIVES

Bayes theorem describes the probability of an event, based on prior knowledge of conditions that might be related to the event.

Lies, damn lies, & clinical trials. Paul Young

Understanding Statistics for Research Staff!

Simple Sensitivity Analyses for Matched Samples Thomas E. Love, Ph.D. ASA Course Atlanta Georgia

Research Methodology. Characteristics of Observations. Variables 10/18/2016. Week Most important know what is being observed.

Insulin pump evaluation

3. Fixed-sample Clinical Trial Design

UA College of Medicine-Phoenix Biostatistics and Study Design Service. Introduction

Overview of Standard Phase II Design Issues

Psychology Research Process

Lecture Notes Module 2

Transcription:

NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!! BERD Pizza & Pilots November 18, 2013 Emily Van Meter, PhD Assistant Professor Division of Cancer Biostatistics

Overview Why do we need a sample size calculation??? What are the essential factors needed to calculate sample size? Other Considerations Types of Hypotheses Types of Endpoints How many groups?? HOW CAN WE HELP YOU?!

Why do we need to calculate sample size?!?!?

Starting Point Starts with your questions and endpoints Think of the data you will be collecting AND the analyses on this data Requires knowledge of the clinical setting

Reasons for Estimating N To achieve reasonable precision of the estimate of interest To ensure adequate statistical power for the hypothesis test Sample size should reflect what is needed for the PRIMARY aim and analysis of the study Needed to determine your budget

Main Question: Sample Size Question What sample size is required to ensure a _ of detecting a at level _?

Sample Size Question Study size should be enough to test your primary hypothesis..and should be enough to examine secondary hypotheses BUT WHAT IS ENOUGH??

OK fine you made your point sample size calculations are important! What factors do I need to calculate my sample size??

Sample Size Parameters Remember the Greeks: = alpha = Probability of a Type I Error = beta = Probability of a Type II Error 1- = POWER = clinically relevant difference*** = standard deviation will be needed too

Error Rates - Alpha A type I error occurs when a true null hypothesis is rejected In the superiority setting this is falsely claiming a difference In the non-inferiority setting this is falsely claiming a similarity This is called the significance level of a test

Choosing α carefully Because is chosen by the investigator, it is under his control and is known Thus when you reject H0, you know the probability of a Type I error is chosen a priori Usually set at alpha = 0.05 Sometimes see alpha = 0.10 or 0.15 in very exploratory phase II settings (not as common)

Error Rates - Beta A type II error occurs when we fail to reject a false null hypothesis In the superiority setting this is falsely claiming no difference In the non-inferiority setting this is falsely claiming a difference = P(fail to reject H0 H0 false) 1- = Power Usually see power at 80% - 90%... Never below 80%!!!

Type II Error and Power Why should we be concerned about power? The power of a test tells us how likely we are to reject the null hypothesis given that the alternative hypothesis is true If the power is too low, then we have little chance of rejecting the null even if the alternative is true What is the cause of low power? Invariably, it is an inadequate sample size

α and β and Statistical Considerations Because we have these two types of error and one is potentially possible in any decision, we NEVER say that we have proved that H0 is true or that H0 is false!!! Proof implies that there is no possibility for error Instead we say that the data support or fail to support the null hypothesis (i.e. reject or fail to reject H0, respectively) Statistical significance does not imply clinical significance

Clinically Relevant Difference Minimum clinically important difference, MCID ( Δ ), in the outcome measure Usually get some information from pilot data or other published results Another tough piece of information to get Purely clinically driven what amount of treatment effect will change clinical practice?

MCID MCID is not necessarily what you observe in previous pilot studies You may have observed the proportion of good outcome of 80% in the pilot study as compared to 30% in historical controls - but is that difference of 50% an MCID? MCID should be chosen such that it is reasonable to expect it from a particular treatment You may chose MCID of 25% but the pilot studies have shown only 5-10% effect size should you plan a study to detect a 25% effect size anyway?

OK so I have the basics now I m done right?! NEVER!

Other things to consider! Type of Hypothesis Superiority, Non-inferiority, equivalence, estimation Type of Endpoint!! Continuous, Binary, Ordinal, Time to Event Type of test 1-sided or 2-sided? Compliance Concerns Drop out rates, loss to follow up, and/or noncompliance (switching treatment arms?) Any interim looks for futility and/or superiority? Number of groups? (1, 2, 3 or more) If more than 1 how will they be allocated? 1:1? 2:1?

Sample Size depends on hypothesis! Hypothesis Testing Approach Superiority Is treatment A BETTER than B? Non-inferiority Is treatment A NOT WORSE than treatment B? Equivalence Is A EQUAL to B (within a reasonable range)? Confidence Interval Approach Estimation Just want to estimate our primary endpoint with a certain amount of precision

Type of Endpoints Continuous and Independent Continuous and NOT Independent Change in blood pressure from pre to post in same individual, repeated measurements Binary or Ordinal Outcomes Proportion of patients that have a successful outcome in your trial (must be clearly defined pre-study!!!) Time to Event Overall survival or progression, need to include accrual and followup times in sample size as well Each one uses a different formula to calculate the appropriate sample size!!! It s important to understand how your data will look!

Treatment Allocation Generally 1:1 (yields best power given total N) Practical More subjects allocated to a new procedure may allow for enthusiasm for the study by investigators or potential subjects Want to gain more information on safety of treatment arm (already have this information for the control arm)

Ethical Treatment Allocation Possibly to minimize exposure by allocating less subjects to more riskier treatment arm or to maximize exposure by allocating more subjects to potentially better treatment arm Some argue that this affects the clinical equipoise of the trial 23

Missing Outcome Data Subject became lost-to-follow-up Subject withdrew consent Subject died No other reason should exists for missing outcome data!

Protocol Violations Subject became lost-to-follow-up Subject withdrew consent Subject had not met eligibility criteria Subject/investigator did not comply with treatment regimen Crossover in treatment allocation What about not obtaining Informed Consent? NEED TO CONSIDER THIS IN SAMPLE SIZE CALCULATIONS!

One-sided versus two-sided tests When is a One-Sided Test Acceptable? It is completely inconceivable that the results can go in the opposite direction from that hypothesized Only truly concerned with outcomes in one tail Often see one-sided test at alpha=0.025 (usually alpha/2)

This is so complicated! Are there some easy ways to understand how sample sizes change?

When keeping all other things the same THINGS THAT MAKE SAMPLE SIZE INCREASE!!! Decreasing alpha Increasing power 2-sided vs. 1-sided test Decreasing MCID Keep in mind that could be changing standard deviations and/or means, or proportions, median survival times, etc Decreasing follow up and/or accrual times

Culprit of Underpowered Studies One common mistake in RCT designs is guaranteeing adequate power, not at or above the threshold of clinical significance, but at or above the desired or hoped-for effect size or one based on very optimistic, underpowered, pilot studies. (Kraemer and Kupfer, 2006)

Software Paid Sample Size Programs: nquery, PASS, EaST, SAS Can also calculate sample sizes in R Simon s 2 stage: http://linus.nci.nih.gov/~brb/ PS: Vandy Free Downloadable Program: http://biostat.mc.vanderbilt.edu/wiki/main/power SampleSize CRAB Calculators: http://www.crab.org/resources/statisticaltools.as px

HOW CAN WE HELP YOU?!?! If you get nothing else from this lecture, sample sizes can be somewhat complex and there are a ton of considerations before we can get the correct one for your study! Come talk to us EARLY!!!!! We are actually here to make your lives a bit easier (no promises though!)

What to bring to a meeting with us! Collaborate with entire research team early in the development process!!! What we need from you: Your proposed research question EASY! Primary and secondary outcomes We ll help you make it specific and quantifiable Groups / factors of interest Clinically meaningful detectable difference and variability of observations Can be found from pilot studies and literature Drives sample size needed! We tend to work better when well fed and happy! Just kidding!

Come talk with us! We can take your objectives and help you with sample size calculations Also assist with study design, analysis plans, etc BERD Core Drs. Richard Kryscio, Heather Bush, Richard Charnigo, Emily Van Meter, Arnold Stromberg, Catherine Starnes Website: http://ccts.uky.edu/berd/default.aspx Email contacts: Catherine Starnes (Catherine.starnes@uky.edu) Or Elodie Elayi (elodie.elayi@uky.edu)